Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed ...

it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option ...

The study reveals that AI systems offer promising accuracy in predicting treatment outcomes, particularly when used to ...

The mechanisms of homologous recombination deficiency (HRD) in non-small cell lung cancer (NSCLC) remain understudied, mainly due to the low prevalence of germline or somatic mutations in relevant ...

indication for treating advanced gynecological cancers in patients who had previously treated with three or more chemotherapy regimens and who had tumours that tested positive for homologous ...

Portrai, Inc., Seoul, Republic of Korea, Seoul, Republic of Korea.